Literature DB >> 23398571

Comparison of patient-reported outcome measures in multiple sclerosis.

N Schäffler1, P Schönberg, J Stephan, J-P Stellmann, S M Gold, C Heesen.   

Abstract

BACKGROUND: Patient-reported outcome measurements (PROMS) have been proposed sensitive outcome parameters in multiple sclerosis (MS). In this study, we assessed a German version of the Multiple Sclerosis Impact Scale (MSIS-29) and a revised version of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) in comparison with rater- and physician-based tools.
METHODS: Consecutive MS patients (n = 117) of the MS outpatient unit were included. In addition to MSIS-29 and HAQUAMS, the following parameters were obtained: Expanded Disability Status Scale (EDSS) and modified Multiple Sclerosis Functional Composite (MSFC) [9-hole peg test (9HPT), 25-foot walk test and symbol digit modalities test]. We investigated validity, internal consistency and test-retest reliability as well as correlation between these measures.
RESULTS: Internal consistency (Cronbach's α ≤ 0.96) and test-retest coefficients (ICC ≤ 0.87) of both scales were high and satisfied psychometric standards. Convergent and discriminant validity was supported by direction, magnitude and pattern of correlation with other rater-based measures depending on the functional subdomain. Both MSIS-29 and HAQUAMS correlated with EDSS (ρ = 0.55 vs 0.62), but stronger correlation was found between MSIS-29 and HAQUAMS total score (ρ = 0.90). Both scales distinguished between patient groups of varied disease severity and cognitive impairment.
CONCLUSION: Patient-reported outcome measurements as MSIS-29 and HAQUAMS seem to be valid instruments to detect different impairment levels in comparison with traditional rater-based instruments like EDSS or MSFC.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  multiple sclerosis; quality of life

Mesh:

Year:  2013        PMID: 23398571     DOI: 10.1111/ane.12083

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

Review 1.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

2.  Managing Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention.

Authors:  Jana Pöttgen; Stephanie Lau; Iris Penner; Christoph Heesen; Steffen Moritz
Journal:  Int J MS Care       Date:  2015 May-Jun

3.  Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial.

Authors:  Patrick Altmann; Fritz Leutmezer; Markus Ponleitner; Dominik Ivkic; Nik Krajnc; Paulus Stefan Rommer; Thomas Berger; Gabriel Bsteh
Journal:  Digit Health       Date:  2022-07-11

4.  The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study.

Authors:  Patrick Altmann; Werner Hinterberger; Fritz Leutmezer; Markus Ponleitner; Tobias Monschein; Tobias Zrzavy; Gudrun Zulehner; Barbara Kornek; Rupert Lanzenberger; Klaus Berek; Paulus Stefan Rommer; Thomas Berger; Gabriel Bsteh
Journal:  JMIR Res Protoc       Date:  2021-05-07

5.  Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme.

Authors:  Judith Brand; Sascha Köpke; Jürgen Kasper; Anne Rahn; Imke Backhus; Jana Poettgen; Jan-Patrick Stellmann; Susanne Siemonsen; Christoph Heesen
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

6.  Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.

Authors:  Anne Christin Rahn; Sascha Köpke; Jürgen Kasper; Eik Vettorazzi; Ingrid Mühlhauser; Christoph Heesen
Journal:  Trials       Date:  2015-03-21       Impact factor: 2.279

7.  Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life.

Authors:  Theresa Krüger; Janina R Behrens; Anuschka Grobelny; Karen Otte; Sebastian Mansow-Model; Bastian Kayser; Judith Bellmann-Strobl; Alexander U Brandt; Friedemann Paul; Tanja Schmitz-Hübsch
Journal:  BMC Neurol       Date:  2017-01-13       Impact factor: 2.474

8.  Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study.

Authors:  Gill A Webster; Dalice A Sim; Anne C La Flamme; Nancy E Mayo
Journal:  Pilot Feasibility Stud       Date:  2017-11-16

Review 9.  Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

Authors:  Peter Joseph Jongen
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

Review 10.  Optimizing treatment success in multiple sclerosis.

Authors:  Tjalf Ziemssen; Tobias Derfuss; Nicola de Stefano; Gavin Giovannoni; Filipe Palavra; Davorka Tomic; Tim Vollmer; Sven Schippling
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.